Ablacon is developing an advanced mapping system to guide the treatment of atrial fibrillation. Ablacon's novel algorithm uses artificial intelligence to analyze and visualize the flow of action potentials, or Electrographic Flow, within the heart in order to identify sources and drivers of atrial fibrillation the most common cardiac arrhythmia worldwide. The map of the Electrographic Flow can help to guide physicians in targeted catheter ablation therapy.
Cortica is a leading provider of advanced neurological therapies for children with autism and other developmental differences. It offers in-home, in-clinic, and telehealth services that empower families to achieve long-lasting, transformative results.
CV Ingenuity (acquired by COV)
CV Ingenuity is focused on improving patient outcomes in the treatment of peripheral arterial disease (PAD) by providing solutions to relieve vascular obstructions, inhibit restenosis, and allow natural vessel healing. The company's core technology is a Drug Coated Balloon (DCB) platform with a novel, proprietary, tunable, rapid-release system. CVI was acquired by Covidien (now Medtronic) in 2012.
EPIX Therapeutics (acquired by MDT)
EPIX Therapeutics, formerly Advanced Cardiac Therapeutics, designs and manufactures a catheter-based system for the treatment of patients with atrial fibrillation. The company's mission is to dramatically improve the treatment of atrial fibrillation through the introduction of products based on its proprietary catheter and generator system. EPIX's technology is the only system in the world to leverage three unique capabilities: temperature sensing and feedback, low irrigation flow rates, and high resolution electrogram attenuation. EPIX was acquired by Medtronic in 2019.
EPMap-System is developing a suite of technologies to be used in electrophysiology procedures, including a 3D mapping and navigation system with an integrated electrical signal recording system, a radiofrequency ablation generator, and an irrigation pump. The system received a CE Mark in 2016 and is available commercially in Europe and other geographies around the world.
Spirox (acquired by ENTL)
Spirox is committed to improving the quality of life for patients suffering from nasal obstruction. The Menlo Park-based company's first product—the LATERA absorbable nasal implant—is designed to address one of the most common, yet undertreated, causes of nasal obstruction today, nasal valve collapse (NVC). In 2017, Spirox was acquired by Entellus, which was subsequently acquired by Stryker.
Verix Health is an interventional oncology company developing a suite of actively steerable surgical devices enabling minimally invasive diagnosis and treatment of lesions in difficult-to-access anatomies. Its technology has the potential to reduce trauma to patients leading to fewer complications, shorter hospital stays, and reduced costs to hospitals and payers.
"I chose to work with Ajax because they know the magic of how to build great healthcare companies, as evidenced by an incredible track record as operators in multiple therapeutic areas over the past two decades. They identify clear areas of unmet need, assemble incredible teams to bring forward meaningful innovation, and drive relentless focus to build shareholder value. They have an operator’s mindset when we encounter problems or see opportunities – they aren’t advising from the sidelines; they are with me in the trenches. A start-up can always be doing 100 things, but only a few of them really matter. They cut through the distractions and focus on what matters to the customer and employees. They are also really fun to work with – they’re all about humility and laughter, which have been infused into the culture of our company."